Clinical Evidence on Apatinib in Treating Chemotherapy-Refractory Metastatic Esophageal Squamous Cell Carcinoma

Review Data

Purpose and Significance of Study: The manuscript describes a study of the treatment of metastatic esophageal squamous cell carcinoma (where cemotherapy had failed) using apatinib, which was successful. The study was conducted on a small number (26) of the chinese population.

 

Fit with Scope of Journal: The manuscript is of very high interest for the journal Clinical Oncology and Research.

 

o   The manuscript contains a few minor errors (already corrected in the galley proof) listed below –

 

In the Title –

 

·       It must be re-phrased as “Clinical Evidence for Successful Treatment of Chemotherapy-Refractory Metastatic Esophageal Squamous Cell Carcinoma Using Apatinib”.

In the Abstract –

 

·       In the 1st sentence, “are” must be replaced with “have”.

·       In the 2nd sentence, “who failed first-line chemotherapy” must be replaced with “where first-line chemotherapy failed”.

·       In the 7th sentence, “commonest” must be replaced with “most common”, and “treatment related” must be hyphenated.

In the Introduction –

 

  In the 1st paragraph –

·       In the 4th sentence, “undergo” must be replaced with “undergoing”.

  In the 2nd paragraph –

·       In the 2nd sentence, “strategy” must be replaced with “strategies”, and “comparing” must be replaced with “comparison”.

In the Methods –

 

  Under Bioinformatics data mining –

·       “,” must be inserted before “including” each time throughout the paragraph.

  Under Patients –

·       In the 3rd sentence, “who” must be inserted before “received”.

·       In the 5th sentence, “Metastasis” must be in plural, i.e., “Metastases”.

·       In the 8th sentence, “following” must be replaced with “follows”.

  Under Treatment –

·       “The” must be inserted at the beginning of the 1st, 7th and 8th sentences.

·       In the 3rd sentence, “Progression free” must be hyphenated.

In the Results –

 

  Under Gene expression of HER2, KDR and VEGF in EC cohorts –

·       In the 2nd sentence, “relative” must be replaced with “relatively”.

·       In the last sentence, “,” must be removed, and “but also may” must be replaced with “but may also”.

  Under Treatment efficacy –

·       In the 5th sentence, “,” must be inserted after “in another patient”.

·       In the 6th sentence, “who” must be inserted before “experienced”.

In the Discussion –

 

  In the 1st paragraph –

·       In the 4th sentence, “therapy” must be replaced with “therapies”.

  In the 2nd paragraph –

·       In the 1st sentence, “suggests” must be replaced with “suggest”, “the” before “metastatic” must be removed, and “failed to” must be replaced with “the failure of”.

·       In the 2nd sentence, “on” after “inhibition” must be replaced with “of”, and “controlling” must be replaced with “control”.

·       In the 3rd sentence, “comparing” must be replaced with “comparison”.

  In the 3rd paragraph –

·       In the 3rd sentence, “,” after “EAC” must be replaced with “;”.

Author Info

Leiming Guo Chengliang Yang Chunyu He Ke Li Lei Qiao Shuning Xu Xiaoyuan Wu Ying Liu

Corresponding Author

Ying Liu
Department of Medical Oncology, Zhengzhou University Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, Henan, China

Article Info

Article Type

Research Article

Publication history

Received: Wed 11, Mar 2020
Accepted: Mon 30, Mar 2020
Published: Wed 08, Apr 2020

Copyright

© 2023 Ying Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.03.08